Therapeutic effect and mechanism of bone marrow mesenchymal stem cell-derived exosomes on traumatic brain injury through the ERK signaling pathway.

Authors

Yun Zhang, Qingli Wang, Yunlong Wang, Fengquan Gao, Weidong Wu, Qingyu Meng

Published in

Folia neuropathologica. Volume 64. Issue 2. Pages 178-185.

Abstract

The aim of this study was to investigate the effect and possible mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exo) on traumatic brain injury (TBI) in order to provide new strategies for clinical treatment of TBI.
Thirty-two healthy male rats were randomly divided into the control group, model group, model control group, and mesenchymal stem cell (MSC) exosome group, with 8 rats in each group. TBI model rats were established using Feeney's free-falling method. Bone marrow mesenchymal stem cells were isolated and cultured, their exosomes were extracted, and MSC exosomes were injected into the bilateral medial hippocampus of rats in the model control group and MSC exosome group. A Morris water maze was used to detect behavioral indicators in each group; hematoxylin-eosin (HE) staining was used to observe the morphological changes of rat hippocampal neurons; an immunohistochemical method was used to detect the expression of the protein Erk/P-Erk in the Erk signaling pathway of rat hippocampal cells; RT-PCR and Western blot were used to detect the mRNA and protein expression levels of b-catenin and cyclin D1.
Compared with the model control group, the MSC exosome group showed a reduced escape latency, as well as an increased number of platform crossings and longer time spent in the platform quadrant. Compared with the model group and the model control group, the lateral compartments of brain tissue in rats in the MSC exosome group did not widen significantly. The arrangement gradually became orderly and compact, with some local areas of looseness remaining, but overall structural improvement was observed. The Erk/P-Erk, and b-catenin levels in the MSC exosome group increased, and the cyclin D1 level decreased.
BMSC-Exo have a significant therapeutic effect on TBI by upregulating the expression of proteins related to the ERK signaling pathway and regulating neuron-related proteins and cell proliferation, which provides a potential new strategy for the treatment of TBI.

PMID:
42704865
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.